TransThera Sciences (Nanjing), Inc.
2617 · HKEX
Public Market Listing
2617HKEX
Live quotes, historical charts, and market capitalization for TransThera Sciences (Nanjing), Inc. are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Aurora A/B kinase (with secondary FGFR1/2/3, VEGFR1, JAK1/2, CSF1R inhibition)Small molecule | Breast CancerBiliary Tract Cancer HR+/HER2- Metastatic Breast Cancer, Cholangiocarcinoma |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
Est. primary completion 2026-12 · NCT05948475 · CT.gov ↗
What to watch
2027 (1)
June 2027 (1)
Est. primary completion 2027-06-30 · NCT07498478 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
Est. primary completion 2028-12-31 · NCT07871110 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Est. primary completion 2029-12-31 · NCT07328919 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.